美诺华：全资子公司获得利奥西呱片药品注册证书

Core Viewpoint - Meheco's wholly-owned subsidiary, Meheco Tiankang, has received the drug registration certificate for Liosiguat tablets from the National Medical Products Administration, enhancing the company's market competitiveness in the treatment of chronic thromboembolic pulmonary hypertension and arterial pulmonary hypertension [1] Group 1: Company Developments - The drug Liosiguat acts as a soluble guanylate cyclase (sGC) agonist, expanding blood vessels through the NO-sGC-cGMP pathway [1] - Meheco Tiankang is now qualified to produce and sell Liosiguat tablets in the domestic market following the approval [1] - The approval marks a significant milestone for Meheco Tiankang, as it joins two other approved companies, Qilu Pharmaceutical and Jiangsu Huayang Pharmaceutical, in the domestic market [1] Group 2: Market Potential - The global sales forecast for Liosiguat tablets in 2024 is approximately $494.16 million, with expected sales in China around $10.38 million [1] - The approval of Liosiguat tablets is expected to enhance the company's product competitiveness in a growing market [1] Group 3: Future Considerations - Future sales of Liosiguat tablets may be influenced by various uncertainties, including policy changes, market demand, and competition from similar drugs [1]